Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | FAP | Q12884 | 3/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.59 |
| ▸ | PREP | P48147 | 1/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272580 | 0.83 | DPP4 (0.62) | DPP4ALDH1A1 | |
| SCHEMBL6242373 | 0.83 | TDP1 (0.59) | DPP4KCNH2FAPDPP9DPP8 | |
| SCHEMBL14102471 | 0.81 | KLK5 (0.54) | DPP4KCNH2FAPDPP9PREP | |
| SCHEMBL14102477 | 0.81 | ALDH1A1 (0.49) | DPP4KCNH2FAPDPP9PREP | |
| SCHEMBL8377886 | 0.81 | DPP4 (0.94) | DPP4DPP9DPP8DPP7 | |
| SCHEMBL7858456 | 0.81 | DPP4 (0.94) | DPP4DPP9DPP8DPP7 | |
| SCHEMBL7852579 | 0.81 | DPP4 (0.94) | DPP4DPP9DPP8DPP7 | |
| SCHEMBL8377973 | 0.81 | DPP4 (0.94) | DPP4DPP9DPP8DPP7 | |
| SCHEMBL4913509 | 0.80 | DPP4 (0.53) | DPP4DPP9DPP8DPP7 | |
| SCHEMBL4913502 | 0.80 | DPP4 (0.53) | DPP4DPP9DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | DPP4 1/4885KCNH2 2009/4885FAP 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.